The drug Olaparib reduces the risk of death in high-risk and hereditary early breast cancer by 32%, with mutations in the BRCA1 and BRC2 genes, according to the latest results of the Olympia study presented on Wednesday by its principal investigator, Andrew Tutt, in a virtual plenary session of the European Society for Medical Oncology (ESMO).
These data update those published in June 2021, which already demonstrated a 42% reduction in the risk of relapse in patients with BRCA1 and BRCA2 mutations, the genes involved in the development of hereditary breast cancer, EFE review.
The results of this second analysis demonstrate both a statistically and clinically significant improvement in overall survival (OS) after one year of olaparib as adjuvant treatment – add-on therapy given after primary treatment – compared to placebo.
.-
Specifically, a 32% reduction in the risk of death was shown in patients with high-risk HER2-negative early breast cancer and BRCA germline mutations.
“Olympia shows that Olaparib reduces the risk of cancer recurrence and increases overall survival in patients with an inherited pathogenic variant in the BRCA1 or BRCA2 genes, which may mark a before and after in the treatment of these patients because they offer the possibility of a cure,” said Dr. Judith Balmaña, who has worked on the study.
These results have already prompted the approval of the drug by the US FDA health authorities last Friday for the target population and in the adjuvant setting, which represents a change in clinical practice.
The treatment was already approved in the metastatic setting and has now been indicated in the early stages of the disease.
By: Agency
–
